SCHEMBL4710798

SCHEMBL4710798

CCOC(=O)c1cccc(C#Cc2cccc(C)n2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.54
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
PKM P14618 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
CYP2C19 P33261 1/20 0.52
THPO P40225 1/20 0.52
KMT2A Q03164 1/20 0.52
GRIN2B Q13224 1/20 0.52
GRM1 Q13255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710493 0.82 GRM5 (0.60) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4319225 0.82 ACACB (0.62) GRM5NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL4711689 0.81 GRM5 (0.66) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL936599 0.81 ACACB (0.53) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL10411917 0.81 ACACB (0.57) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL4713389 0.80 GRM5 (0.65) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4714004 0.78 GRM5 (0.47) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4713592 0.77 GRM5 (0.44) GRM5
SCHEMBL7187490 0.77 ACACB (0.54) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL97217 0.76 SMN1; SMN2 (0.55) NPC1RAB9ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed